Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

This study is being done to answer the following questions: Can adding a drug to the usual treatment for advanced stomach and esophageal cancers make it less likely that these cancers will grow or spread? Can we increase the amount of time advanced stomach and esophageal cancer patients live by adding a drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced stomach and esophageal cancer. The usual approach is defined as care most people get for advanced stomach and esophageal cancer.